Neuroscience News

Scientists Identify New Gene Behind Hereditary Vision Loss

Researchers have identified a new genetic cause of hereditary optic atrophy—a condition that leads to gradual vision loss—by discovering a previously unknown mutation in the PPIB gene. T ...

New genetic variant linked to hereditary optic atrophy and vision loss

A research team from the Medical University of Vienna and the Medical University of Graz has discovered a previously unknown ...
Seeking Alpha

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent ...

Scholar Rock (SRRK) intends to resubmit the apitegromab Biologics License Application (BLA) upon resolution of Catalent Indiana LLC-related observations CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar ...
technologynetworks

Monoclonal Antibody Improves Motor Function in Spinal Muscular Atrophy Patients

A new clinical trial has revealed encouraging results for a muscle-targeting therapy aimed at improving motor function in children and adolescents with spinal muscular atrophy, according to a study ...
Business Insider

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...
The New York Times

Forced Drug Treatment Isn’t Horrific. It’s a Relief.

Mr. Humphreys is a professor of psychiatry at Stanford University and served as senior drug policy adviser in the Obama administration. He is a member of the board of Indivior, which manufactures ...
Medscape

AI-Powered Model Can Classify Types of Optic Nerve Damage

A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...
Medscape

Start Spinal Muscular Atrophy Treatment at Birth?

Oral risdiplam (Evrysdi, Genentech) started in the first 6 weeks of life let most infants with presymptomatic spinal muscular atrophy (SMA) reach motor milestones typical of healthy babies, results of ...
EurekAlert!

Clinical trial shows newborns with spinal muscular atrophy (SMA) can start treatment at birth

Co-first and co-corresponding author Richard Finkel, MD, St. Jude Center for Experimental Neurotherapeutics director and Department of Pediatric Medicine member. “The impact of giving risdiplam soon ...
KING5

Mobile unit offers new hope for rural Snohomish residents battling addiction

MONROE, Wash. — As she climbed aboard Snohomish County's latest tool in battling drug addiction, Nicole Smith-Mathews hoped today would open a door to changing lives for the better. Smith-Mathews, who ...
MarketWatch

Sanofi Geographic Atrophy Treatment Gets FDA's Fast Track Designation

Sanofi said SAR446597, its treatment for geographic atrophy due to age-related macular degeneration, was granted fast-track designation by the Food and Drug Administration. The French drugmaker said ...